Improper use of prior authorization is creating hurdles for Medicaid participants and getting in the way of their ability to access needed care. Prior authorization is generally an insurance company requirement that health care providers obtain approval from a patient’s health insurance plan for a medicine before it will be covered. The Office of Inspector General (OIG) recently uncovered that Medicaid Managed Care Organizations (MCOs), the insurance companies that administer Medicaid plans across the country, are leveraging prior authorization policies to pad their own bottom line.
The OIG shared three main concerns with the improper use of prior authorization:
- Rate of prior authorization denial. In the OIG’s review, they found MCOs denied 1 out of every 8 requests for the prior authorization of services — over twice the denial rate in Medicare Advantage. Several MCOs had denial rates higher than 25%, which is twice the overall rate.
- Limited oversight of denials. State Medicaid agencies reported a lack of reviews on MCO denials. Because of this, many did not collect data and monitor decisions. This lack of transparency means MCOs are not held accountable for their decisions.
- Limited appeals process. Most states do have an appeals process to remedy wrong denials, but this process may be difficult to navigate and burdensome on Medicaid participants, which discourages many patients from advocating for themselves.
In response to this OIG report, Senate Finance Committee Chair Ron Wyden and House Energy and Commerce Committee Ranking Member Frank Pallone, Jr., have launched an investigation into Medicaid managed care prior authorization procedures. Transparency is important for prior authorization requirements, as well as reasonable timelines for prior authorization decisions, to ensure MCO accountability, streamline care and encourage greater shared decision making.
When left unchecked, prior authorization is an obstacle that runs counter to Medicaid’s goals and can:
- Lead to a delay in patients getting the medicines and care they need.
- Interfere with the doctor-patient relationship by preventing providers from being able to select the best medicine for each patient’s individual circumstances.
- Discourage doctors from prescribing the most appropriate therapies.
Medicaid and the Children’s Health Insurance Program (CHIP) provide health coverage for more than 83 million vulnerable Americans, including children and their parents, pregnant women, the elderly and people living with disabilities. This state-federal partnership provides Americans across the country with access to needed medications with low to no cost sharing.
We urge the Centers for Medicare and Medicaid Services (CMS) to step in and collect information on prior authorization, particularly around access to medicines, to determine if MCOs are excessively using this policy to serve their own financial interests. Improving access to medicines in the United States requires a holistic look at the health care system, including insurance companies’ administrative hurdles imposed on patients.
For more information on Medicaid, visit PhRMA.org/Medicaid.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Insurers routinely block seniors’ access to medicines in Medicare Part D
Delivering breakthroughs and lower costs for patients
New study: PBMs and commercial insurers are quietly blocking prescription access
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Ensuring access to affordable medicines for patients through Medicaid
CMS, don’t fall behind the rest of the medical community on obesity
The real cost of denying access to medicines in Medicaid
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Guest Post: My health care vote
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
Key voter insights two months from Election Day
Patient priorities in the 2024 election
Medicaid by the numbers
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
ICYMI: What patients care about this election year
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
Ongoing federal probes shed light on PBM and insurer practices
Critics repeat same, misleading narrative on potential “costs” of new medicines
WTAS: The consequences of consolidation and vertical integration
Providing affordable access to medicines in Medicaid
IRA is already negatively impacting access to medicines in Part D
Insurance data: PBM reform has no material impact on premiums
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
ICYMI: When middlemen get in the way, it’s the patients who lose
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
One year to Election Day: Four voter priorities to watch
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
Manufacturers provided $42 billion in Medicaid discounts in 2021 alone
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
ICYMI: PBM exec admits choosing profits over patients
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
4 Things to know about PhRMA’s new 50-state poll
Three facts about health care spending
AHIP’s latest misinformation campaign & what it’s trying to hide
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
States can support access to medicine as COVID-19 Public Health Emergency ends
Arkansas puts patients first with new share the savings law
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
Holding pharmacy benefit managers accountable
Stopping pharmacy benefit managers from “gaming the system”
Senate hearing to examine bipartisan reforms to rein in middlemen
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
Study finds hepatitis C cure saved Medicaid $15 billion
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
In their own words: Financial barriers exacerbate access challenges for insured Americans
Medicare Part D open enrollment and what recent changes mean for beneficiaries
New data show how insurers and middlemen shift Rx costs onto patients
In their own words: Insured Americans struggle to navigate complex coverage
Many seniors are paying more for Part D medicines than their insurer
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
Busting 3 Myths About Copay Coupons
Mental Illness Awareness Week – A time for reflection
Navigating the patient experience: Burdens and barriers standing between patients and their care
Making coupons count for patients at the pharmacy counter
Insulin and reconciliation
Making coupons count for patients with HIV
Patients win as West Virginia implements first-in-nation share the savings policy
3 things voters are concerned about when it comes to their health care coverage
Copay assistance is a lifeline for patients. So why are insurers blocking it?
New poll shows voters sounding the alarm on health insurance companies and PBMs
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Report finds PBMs are increasingly restricting patient access to medicines
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
Study finds insurance barriers disproportionately burden patients with chronic illness
5 public opinion polling trends to watch
Analysis: States can help patients save nearly $1,000 annually on their medicines
How standardized plans can improve patients’ access to medicines
The patient experience: Uncovering the barriers to care for insured Americans
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
PhRMA submits comments urging CMS to withdraw coverage proposal
Medicaid 101: Three charts on access and spending
New comments outline ways to counteract cost-shifting insurance trends
Patients need to pay less for their medicines. States can help.
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
The patient experience: Insurance design hurdles lead to access issues for too many Americans
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
Insurers shift medicine costs to patients with severe chronic illnesses
Tennessee’s Medicaid demonstration fails patients
Election insights: Voter priorities in the states
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Recent administration actions undermine patient assistance programs
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
PhRMA submits comments to CMS on Medicaid proposed rule
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
New report shows better diabetes management saves money and improves patient outcomes
ICYMI: New report outlines steps for greater transparency in health care
Increased use of prior authorization in Medicaid is blocking access for patients
Health Insurance
Medicaid
Increased use of prior authorization in Medicaid is blocking access for patients
Increased use of prior authorization in Medicaid is blocking access for patients